Replies to post #179008 on Biotech Values

[DewDiligence]

MRK/IDIX—I don't think the nuke IP was the impetus for the buyout.

Without IDIX's IP vig, the buyout could still have occurred, but the deal price wouldn’t have been $3.85B, IMO.